Navigation Links
More radionuclide therapy is better for prostate cancer patients
Date:11/1/2011

Reston, Va. (November 1, 2011) For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

Approximately 50 percent of prostate cancer patients develop bone metastases that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of bone metastasis often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.

The retrospective study, "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis," reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groupsthose who received one therapy, two therapies or three or more therapies.

"Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer," noted lead author of the study Hans-Juergen Biersack, MD. "For this study, we developed 188Re-HEDP as a novel radiopharmaceutical whichdue to it is short half life of 19 hoursmakes sequential therapy possible."

The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scoresa grading system used to evaluate the prognosis of men with prostate cancerfor each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.

In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.

"For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases," noted Biersack. "The findings support and expand the role of molecular therapy with radioisotopes in oncology."

188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Benefits of radionuclide therapy for neuroendocrine tumors
2. Radionuclide treatment against small tumors and metastases
3. New Multiple Sclerosis Therapy Promising in Early Trial
4. New therapy shows promise for treating cardiovascular disease
5. Speech Therapy Key to Stroke Rehab, But Many Miss Out
6. Scientists make strides toward drug therapy for inherited kidney disease
7. Ovarian Tumors May Develop Years After Fertility Therapy
8. Statin therapy fails to slow progression of atherosclerosis in pediatric lupus patients
9. Through-the-nipple breast cancer therapy shows promise in early tests
10. Compound found in common wart treatment shows promise as leukemia therapy
11. Timing for clinical trials for stem cell therapy in spinal cord injuries is right
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the ... , “There were things that his parents and teachers had asked of him that he ... he was going to defy the Almighty Creator. There were some who would have felt ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble ... without requiring a referral. Trimble Dental offers a variety of services to ... dental implants. Whether patients have discolored, crooked or missing teeth in Eau Claire, ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the second major ... in 2014. It is the culmination of collaborative efforts by members of ... OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided key technical ...
(Date:3/27/2017)... Boston, MA (PRWEB) , ... March 27, 2017 ... ... NEJM Group, the organization behind the New England Journal of Medicine and NEJM ... , NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017  BERG, a biopharmaceutical company uncovering ... approach, today announced that the company,s Interrogative ... new data using a cold-induced model to ... Joslin Diabetes Center led the investigation with ... analysis of samples.  The findings were published ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... mixed colors as the NASDAQ Composite closed the trading ... 0.29% lower; and the S&P 500 was down 0.08%. ... of nine sectors finishing the day in green. Pre-market ... stocks: Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: